Targeted therapy in non-small-cell lung cancer—is it becoming a reality?
F Janku, DJ Stewart, R Kurzrock - Nature reviews Clinical oncology, 2010 - nature.com
Abstract Treatment outcomes in advanced or metastatic non-small-cell lung cancer (NSCLC)
remain unsatisfactory, with low long-term survival rates. Palliative chemotherapy offers a …
remain unsatisfactory, with low long-term survival rates. Palliative chemotherapy offers a …
Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation–positive non-small cell lung cancers: an update for recent advances in therapeutics
C Chung - Journal of Oncology Pharmacy Practice, 2016 - journals.sagepub.com
The presence of activating gene mutations in the epidermal growth factor receptor of non-
small cell lung cancer patients is predictive (improved progression-free survival and …
small cell lung cancer patients is predictive (improved progression-free survival and …
Concurrent cetuximab and radiotherapy after docetaxel–cisplatin induction chemotherapy in stage III NSCLC: Satellite—A phase II study from the Swedish Lung …
A Hallqvist, G Wagenius, H Rylander, O Brodin… - Lung Cancer, 2011 - Elsevier
BACKGROUND: Several attempts to increase the locoregional control in locally advanced
lung cancer including concurrent chemotherapy, accelerated fractionation and dose …
lung cancer including concurrent chemotherapy, accelerated fractionation and dose …
The value of biomarkers in patients with sarcomatoid carcinoma of the lung: molecular analysis of 33 cases
X Jiang, Y Liu, C Chen, Z Zhan, Q Yan, Y Guo… - Clinical Lung Cancer, 2012 - Elsevier
Background Sarcomatoid carcinoma (SC) of the lung is a rare histologic group of lung
cancers with a poor prognosis. To better understand the prognosis of lung SC, in this study …
cancers with a poor prognosis. To better understand the prognosis of lung SC, in this study …
Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line?
C Gridelli, P Maione, A Rossi, ML Ferrara… - The …, 2009 - academic.oup.com
Although substantial progress has been made in the therapeutic options currently available
for patients with advanced non-small cell lung cancer (NSCLC), the overall survival profile …
for patients with advanced non-small cell lung cancer (NSCLC), the overall survival profile …
[HTML][HTML] Erlotinib (tarceva) for the treatment of non–small-cell lung cancer and pancreatic cancer
CM Rocha-Lima, LE Raez - Pharmacy and Therapeutics, 2009 - ncbi.nlm.nih.gov
Erlotinib (Tarceva) is a small-molecule, orally dosed, anti-cancer drug that inhibits the
epidermal growth factor receptor. Randomized, controlled clinical studies have …
epidermal growth factor receptor. Randomized, controlled clinical studies have …
[HTML][HTML] The roles of epidermal growth factor receptor (EGFR) inhibitors in the management of lung cancer
A Al Olayan, H Al Hussaini, AR Jazieh - Journal of infection and public …, 2012 - Elsevier
Targeting epidermal growth factor receptor (EGFR) is an important treatment option for non-
small cell lung cancer (NSCLC). These targeted therapies have been studied extensively in …
small cell lung cancer (NSCLC). These targeted therapies have been studied extensively in …
Maintenance therapy in nonsmall‐cell lung cancer: A new treatment paradigm
TSK Mok, SS Ramalingam - Cancer, 2009 - Wiley Online Library
Systemic chemotherapy with platinum‐based regimens provides modest improvements in
survival and quality of life for patients with advanced‐stage nonsmall‐cell lung cancer …
survival and quality of life for patients with advanced‐stage nonsmall‐cell lung cancer …
[HTML][HTML] 多西他赛与吉非替尼序贯应用对人肺腺癌细胞SPC-A1 生长及信号蛋白的影响
张文颖， 张为民， 王林， 郑静娴， 肖锋 - Chinese Journal of Lung …, 2011 - ncbi.nlm.nih.gov
背景与目的已经证明: 化疗联合表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor
receptor-tyrosine kinase inhibitors, EGFR-TKIs) 与单独化疗比较治疗晚期非小细胞肺癌并不能 …
receptor-tyrosine kinase inhibitors, EGFR-TKIs) 与单独化疗比较治疗晚期非小细胞肺癌并不能 …
[HTML][HTML] 分子靶向药物应用于非小细胞肺癌维持治疗的研究进展
单利 - Chinese Journal of Lung Cancer, 2010 - ncbi.nlm.nih.gov
在发达及发展中国家, 肺癌仍是癌症死亡的重要原因[1]. 其中, 非小细胞肺癌(non-small cell lung
cancer, NSCLC) 占80%-85%, 并且70% 以上NSCLC 患者临床确诊时处于复发或转移性的 …
cancer, NSCLC) 占80%-85%, 并且70% 以上NSCLC 患者临床确诊时处于复发或转移性的 …